NDA 216403 · Travere
Filspari
Sparsentan · Oral · Endothelin Receptor Antagonist; Angiotensin 2 Receptor Blocker
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Feb 17, 2023: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Feb 17, 2023
Approved uses
4
Original approval plus efficacy supplements
Registered trials
10
2 Phase 3, 3 recruiting
FAERS reports
6,767
1,116 serious, 37 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY and EMBRYO-FETAL TOXICITY Because of the risk of hepatotoxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Under the FILSPARI REMS, prescribers, patients, and pharmacies must enroll in the program [see Warnings and Precautions ( 5.1 , 5.2 )] . Hepatotoxicity Some Endothelin Receptor Antagonists (ERAs) have caused elevations of aminotransferases, hepatotoxicity, and liver failure. In clinical studies, elevations in aminotransferases (ALT or AST) of at least 3-times the Upper Limit of Normal (ULN) have been observed in up to 3.5% of FILSPARI-treated patients, including cases confirmed with rechallenge. Measure transaminases and bilirubin before initiating treatment and then every 3 months during treatment. Interrupt treatment and closely monitor patients who develop aminotransferase elevations more than 3-times ULN [see...
What it is approved for
From the label in effect Apr 9, 2026.
FILSPARI is an endothelin and angiotensin II receptor antagonist indicated: • To slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression ( 1.1 , 12.1 , 14.1 ). • To reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome ( 1.2 , 12.1 , 14.2 ). 1.1 Immunoglobulin A Nephropathy FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression [see Clinical Pharmacology ( 12.1 ), Clinical Studies ( 14.1 )]. 1.2 Focal Segmental Glomerulosclerosis FILSPARI is indicated to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome [see Clinical Pharmacology ( 12.1 ), Clinical Studies ( 14.2 )].
Mechanism: Sparsentan is a single molecule with antagonism of the endothelin type A receptor (ET A R) and the angiotensin II type 1 receptor (AT 1 R). Sparsentan has high affinity for both the ET A R (Ki= 12.8 nM) and the AT 1 R (Ki=0.36 nM), and greater than 500-fold selectivity for these receptors over the endothelin type B and angiotensin II subtype 2 receptors. Endothelin 1 and angiotensin II are thought to be involved in the pathogenesis of IgAN and FSGS via the ET A R and AT 1 R, respectively.
Therapeutic areas: Cardiovascular and metabolic · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 13, 2026 Supplement 6 · Efficacy OrphanLetterLabelMedication Guide
- Aug 27, 2025 Supplement 5 · Efficacy OrphanLabelMedication GuideLetter
- Sep 5, 2024 Supplement 3 · Efficacy · priority review OrphanLabelLetter
- Feb 17, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelMedication GuideLetter
2 products under this application
- FILSPARI · SPARSENTAN 400MG · TABLET, ORAL · Prescription
- FILSPARI · SPARSENTAN 200MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sparsentan" as an intervention, any sponsor and status, largest first.
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyPivotal-lookingCompleted
Travere Therapeutics, Inc.Industry
NCT03762850 · 406 participants · Start Dec 11, 2018 · Primary completion Aug 7, 2023
Drug: sparsentan; irbesartan and 1 more · For: Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Homewood, Alabama; Glendale, California · 162 sites in all
- Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)Pivotal-lookingCompleted
Travere Therapeutics, Inc.Industry
NCT03493685 · 371 participants · Start Apr 17, 2018 · Primary completion Mar 20, 2023
Drug: sparsentan; Irbesartan · For: Focal Segmental Glomerulosclerosis
Sites: Mesa, Arizona; Phoenix, Arizona; Los Angeles, California · 226 sites in all
- Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisPivotal-lookingCompleted
Travere Therapeutics, Inc.Industry
NCT01613118 · 109 participants · Start Mar 2014 · Primary completion Jun 2016
Drug: RE-021 (Sparsentan); Irbesartan · For: Focal Segmental Glomerulosclerosis
Sites: San Diego, California; Torrance, California; Denver, Colorado · 33 sites in all
Travere Therapeutics, Inc.Industry
NCT05003986 · 67 participants (planned) · Start Aug 12, 2021 · Primary completion Mar 12, 2027
Drug: Sparsentan; Sparsentan and 1 more · For: Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy and 2 more
Sites: Los Angeles, California; Wilmington, Delaware; Miami, Florida · 47 sites in all
Travere Therapeutics, Inc.Industry
NCT05856760 · 48 participants · Start May 19, 2023 · Primary completion Oct 14, 2024
Drug: Sparsentan · For: Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Chula Vista, California; Garden Grove, California · 30 sites in all
Travere Therapeutics, Inc.Industry
NCT05562362 · 47 participants · Start Jun 18, 2020 · Primary completion Nov 12, 2020
Drug: RE-021, sparsentan · For: Healthy Subjects
Sites: Nottingham, United Kingdom
- ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)Active, not recruiting
University of EdinburghAcademic, hospital or other
NCT05630612 · 32 participants · Start Dec 8, 2022 · Primary completion Jul 18, 2024
Drug: Sparsentan · For: ANCA Associated Vasculitis; Cardiovascular Diseases; Kidney Diseases
Sites: Edinburgh, United Kingdom
University of LeicesterAcademic, hospital or other
NCT04663204 · 24 participants (planned) · Start Dec 10, 2020 · Primary completion Dec 31, 2027
Drug: Sparsentan · For: Immunoglobulin A Nephropathy; Kidney Diseases; Glomerulonephritis, IGA and 3 more
Sites: Cambridge, United Kingdom; Salford, United Kingdom; Edinburgh, United Kingdom · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness984
- fatigue887
- hypotension750
- off label use456
- nausea455
- headache403
- product use in unapproved indication390
- product administration error369
- peripheral swelling354
- pruritus317
- product dose omission issue278
- blood pressure decreased268
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 632 |
| 2024 | 1,221 |
| 2025 | 2,395 |
| 2026 | 2,508 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Filspari (Sparsentan)
2024 spending
$24.3M
Beneficiaries
323
2,074 claims
Per beneficiary
$75,225
$372.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $4,777,836 |
| 2024 | $24,297,520 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Interventions for focal segmental glomerulosclerosis in adults.
Hodson EM, Sinha A, Cooper TE · Cochrane Database Syst Rev 2022 · Systematic Review
- Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Elnaga AAA, Alsaied MA, Elettreby AM, et al. · BMC Nephrol 2024 · Systematic Review, Meta-Analysis
- Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu ID, Willis NS, Craig JC, et al. · Cochrane Database Syst Rev 2025 · Meta-Analysis, Systematic Review
- DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Trachtman H, Nelson P, Adler S, et al. · J Am Soc Nephrol 2018 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Travere
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.